A Perfect Storm or a Window of Opportunity? Navigating Rare Disease Policy at a Critical Crossroads

This piece was prepared by APCO’s UK Health team

On Friday, 27 February, the UK’s National Institute for Health and Care Excellence (NICE) published its first-ever quality standard for rare diseases—a landmark framework promising timely diagnosis, equitable access to treatments and coordinated care for the millions of patients and family members who are collectively affected by rare conditions across England and Wales. It’s an undeniably positive step, signaling real commitment to closing gaps in rare disease care. Combined with recent improvements to NICE’s cost-effectiveness thresholds for rare disease treatments, the policy environment appears more favorable than it has been in years. 

Yet, beneath this optimism lies a more complex reality. As Eric Power, interim director, Centre for Guidelines at NICE, noted, the quality standard aims to deliver “more timely, coordinated and equitable care.” But can these ambitions be realized when the very supply chains that deliver rare disease treatments are under unprecedented strain?  

Fragile Foundation

Rare disease treatments depend on highly specialized, globally interconnected supply chains. With small patient populations and limited manufacturing capacity, even minor disruptions can have devastating consequences. Active pharmaceutical ingredients (APIs) are often sourced from single suppliers across multiple countries. Specialized biologics require unique facilities and expertise that cannot be quickly replicated or replaced. 

This fragility is now colliding with significant tariff uncertainty. As the UK and the United States negotiate a pharmaceutical trade deal, the specter of new tariffs on APIs, finished medicines and clinical trial materials looms large. For pharmaceutical companies already operating on thin margins in rare disease development, this uncertainty is forcing difficult choices: Should they stockpile inventory? Relocate manufacturing? Delay investment in new therapies? 

Timing Paradox 

Just as NICE is raising the bar for rare disease access through improved quality-adjusted life year (QALY) thresholds—a metric for medical treatments that combines length and quality of life—and comprehensive care standards, trade policy threatens to undermine the very infrastructure needed to deliver on these promises. Sue Farrington, chair of the Rare Autoimmune Rheumatic Disease Alliance, described the new quality standard as being about “closing the gaps”. Yet tariff uncertainty risks opening new ones—gaps between policy ambition and patient reality. 

The UK-U.S. trade negotiations represent either a critical threat or a generational opportunity. If tariffs are imposed on rare disease treatments or their components, costs will rise, supply chains will be disrupted and patient access will suffer—directly contradicting NICE’s quality standard commitments to timely and equitable care. Conversely, if negotiators secure tariff exemptions and regulatory alignment for rare disease medicines, the UK could strengthen its position as a leader in rare disease innovation and care. 

Strategic Navigation

The pharmaceutical industry finds itself at a critical juncture where clinical excellence, health economics, trade policy and patient advocacy must align. Companies developing rare disease treatments cannot afford to view these as separate challenges. NICE’s quality standard demands equitable access. Improved QALY thresholds create pathways to reimbursement, but without stable supply chains protected from tariff disruption, neither matters. 

This moment requires more than reactive crisis management. It demands proactive, strategic engagement across multiple stakeholder groups—from policymakers and regulators to patient organizations and trade negotiators. Companies must clearly articulate how tariff policy impacts their ability to deliver on NICE’s vision. They must build coalitions that bridge the traditional divides between health policy and trade policy. And they must do so while maintaining trust with patients, clinicians and the broader health care system. 

Path Forward

The publication of NICE’s quality standard should be celebrated as progress. Even so, progress requires infrastructure—both physical supply chains and policy frameworks—that supports rather than undermines access. As trade negotiations continue, pharmaceutical leaders must ensure that rare disease treatments are protected, that supply chain resilience is prioritized, and that the promise of improved NICE standards translates into real-world patient benefit. 

For rare disease patients, the stakes are too high for this alignment to be left to chance. The policy environment is shifting rapidly. Companies who can navigate its complexity strategically—bringing together the right voices, building the right coalitions, and making the case clearly to the right audiences—will be best positioned to turn this moment of uncertainty into lasting opportunity.